Clinical data | |
---|---|
Routes of administration | Oral, intravenous, insufflation |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Unknown |
Metabolism | Hepatic |
Elimination half-life | 5.5 Hours[3] |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.018.567 |
Chemical and physical data | |
Formula | C11H16N2 |
Molar mass | 176.258 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Benzylpiperazine, commonly referred to as BZP is an recreational drug. It is also available with trade names such as "A2", "Frenzy" and "Nemesis",[4] It is a stimulant and may cause Euphoria. People believe it works in a way similar to MDMA. The effects produced by BZP are comparable to those produced by amphetamine. Side-effects include acute psychosis, problems with the kidneys Adverse effects have been reported following its use including acute psychosis and seizures. It does not appear to be very addictive and no deaths have been reported following taking BZP once. There have been at least two deaths which resulted from the combination of BZP and MDMA. Its sale is banned in a few countries, including the United States, Australia, New Zealand and in parts of Europe.[5] However, its legal status is currently less restrictive in some other countries such as Ireland and Canada. The European Union is currently changing its laws to regulate this substance more.